Chemo plus immunotherapy before surgery for mucosal melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of mucosal melanoma that can be removed with surgery (resectable).
- You must have never received immunotherapy (like checkpoint inhibitors) or taxane chemotherapy (like paclitaxel) before.
- Your cancer must not have spread to other parts of the body (no distant metastases).
- You must not have an active autoimmune disease or be on high-dose steroids (over 10 mg prednisone daily).
- You must have good organ function (blood counts, kidney, liver) and be willing to provide tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
This trial tests two drugs given before surgery to shrink melanoma that has spread to lymph nodes. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before surgery for head and neck mucosal melanoma. The goal is to see if this therapy can shrink the tumor and improve outcomes.
This trial tests whether two medications, lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy), given before and after surgery, can help reduce the chance of mucosal melanoma coming back. If you are eligible, you would receive these drugs in addition to your standard surgery.
Hear when a new Resectable Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.